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Abstract: Bone grafting is utilized in nearly all orthopedic subspecialties and in most anatomic 
regions. Bone graft substitutes have the potential to offer similar efficacy as autogenous grafts 
without the morbidity of harvest. Several studies have noted the efficacy of new-generation 
bone substitute products, but few studies have evaluated their safety. This study characterizes 
and quantifies the inflammatory reaction to four different commercially available bone graft 
substitutes, which were examined using the in vivo murine air pouch biocompatibility model. 
One coralline hydroxyapatite product was chosen as an example of a purely osteoconductive 
material. Three demineralized bone matrix products were chosen to represent products that are 
both osteoconductive and osteoinductive. Samples were implanted in a murine air pouch and 
harvested after 14 days in situ. Pouch fluid was extracted, mRNA isolated, and reverse transcrip-
tion polymerase chain reactions carried out to detect interleukin-1 gene expression as a marker 
for inflammation. In addition, multiple histological characteristics were examined to quantify 
cellular responses to the implanted materials. All bone graft substitutes induced a significant 
inflammatory response compared with negative controls. Histology and polymerase chain reac-
tion data indicated that the level of inflammatory reaction was elevated in materials with a higher 
demineralized bone matrix to carrier proportion. The hydroxyapatite product generated a low 
inflammatory reaction. In conclusion, this study used an in vivo model of biocompatibility to 
demonstrate that a significant inflammatory reaction occurs when using implanted bone graft 
substitutes. When choosing a bone grafting method, surgeons should consider both the efficacy 
and safety of methods and materials used. Further studies are necessary to determine the ideal 
bone graft material to maximize efficacy while minimizing morbidity.
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Introduction
Bone grafting is a ubiquitous tool of orthopedic surgery, because it is used in all sub-
specialties and in most anatomic regions. The bone source may be from the patient 
(autograft) or a cadaver (allograft). However, problems exist with both of these sources. 
Harvesting autograft bone prolongs the operative time and may cause significant 
donor-site complications. The use of allograft bone carries the added risk of disease 
transmission as well as the potential for inflammatory or immunologic reactions to 
foreign tissue.
Although autografts remain the gold standard for most bone grafting applications, 
recent advances have suggested that alternatives may be available that offer less 
potential morbidity. There have been significant advances in the development of bone 
graft substitutes over the past decade. If these substitutes can be demonstrated to be 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
13
ORIgInAl ReSeARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JIR.S21411Journal of Inflammation Research 2012:5
efficacious and safe, they provide an appealing alternative 
to conventional bone grafting techniques.1,2
The search for an ideal bone graft substitute was ignited 
in 1965, when Marshall Urist3 first discovered that demin-
eralized bone matrix (DBM) implanted in muscle tissue 
induced bone growth. Since that time, Urist and others 
have promulgated the three properties that are used today to 
describe the activity of any bone graft material: osteoconduc-
tivity, osteoinductivity, and osteogenicity. These properties 
refer to a material that can provide a physical scaffold upon 
which bone can grow, that can stimulate new bone growth 
through various biochemical signaling events, and that can 
provide precursor cells or actual bone cells that can then, in 
turn, cause the propagation of new bone, respectively.4 The 
ideal bone graft would possess all three of these properties. 
For example, a fresh autograft possesses structure, necessary 
signaling molecules, and cells required to produce new bone. 
There are several engineered bone graft substitutes available 
now that possess some, but not all, of these properties.5,6 
DBM has been shown to possess osteoconductive as well as 
osteoinductive properties.7,8 It has also been shown to cause 
new bone formation in vivo.9–13 Therefore, DBM represents 
a promising bone graft alternative, without the morbidities 
mentioned previously.14,15
Unfortunately, there are few or no clinical data to support 
the overall safety or efficacy of these products, particularly 
with regard to immunogenicity. Some products have been 
shown to cause adverse responses in vivo, including neph-
rotoxicity, likely due to the DBM carrier compound.16,17 
Despite this lack of immunological data, the overall use of 
DBM products and the number of available products have 
grown rapidly.18 Therefore, further study appears necessary 
to substantiate that the product is safe and efficacious, in 
addition to determining the best preparation procedures and 
product formulation.
Materials and methods
Murine air pouch model
The care and use of mice were approved by the Animal Inves-
tigation Committee of Wayne State University, Detroit, MI. 
The murine air pouch model for biocompatibility testing was 
used for this investigation.19 Air pouches were created in the 
dorsal subcutaneous tissue of female BALB/c mice. Initially, 
3 mL of air was injected subcutaneously using a 25-gauge 
needle. Air pouches were injected with an additional 1 mL of 
air on alternate days for a total of 5 days. Implantation of the 
study materials was performed on the sixth day, when pouches 
were incised and test material was inserted into the pouch. 
The pouches were then closed using 4–0 Prolene suture. As a 
prophylactic anti-infective, 0.3 mL of sterile phosphate buff-
ered saline containing 1:100 penicillin:streptomycin solution 
was injected using a 25-gauge needle. Mice were randomly 
assigned to one of five groups of six mice. Pouches in the 
first group were incised and injected with sterile phosphate 
  buffered saline solution. The second group was implanted with 
sterile 1.0 mL of ProOsteon® (Interpore Cross, Irvine, CA). 
This compound is a porous hydroxyapatite material repre-
sentative of purely osteoconductive, coralline materials. The 
other three groups were implanted with sterile 1.0 mL of the 
DBM compounds DBX® (Synthes Inc, Paoli, PA), Accell 
Connexus® (Isotis Orthobiologics, Irvine, CA), and Accell 
DBM-100™ (Isotis Orthobiologics). DBX is approximately 
32% DBM by weight in a sodium hyaluronate carrier. Accell 
Connexus contains 70% DBM in a proprietary “reverse-phase 
medium.” Accell DBM-100 is 100% DBM without carrier. 
All mice were sacrificed 14 days after implantation in a CO2 
chamber. The pouches were dissected free from the subcutane-
ous tissues. Each pouch was then carefully cut in half, with 
half of the tissue fixed in formalin and half snap-frozen for 
nucleic acid extraction.
Histologic evaluation and image analysis
Tissue samples were fixed, dehydrated, and embedded in par-
affin blocks. Particular care was taken to maintain the original 
shape and orientation of the sample relative to its position on 
the mouse. Sections were stained with hematoxylin and eosin 
to evaluate the cellular infiltrates within the pouch and pouch 
membrane. A minimum of four separate sections per speci-
men were examined using ImagePro image analysis software 
package (Media Cybernetics, Bethesda, MD). Pouch thick-
ness was measured at six points distributed evenly along the 
circumference of each pouch. The density of nucleated cells 
was measured within the thickness of the pouch membrane 
and within the pouch cavity. The total number of cells was 
measured within at least four representative areas and divided 
by the area in mm2 to determine cellular density, as described 
previously.19 The image analysis utilized nuclear aspect ratio 
to distinguish between mononuclear and fibroblastic cell 
morphology, as described elsewhere.20 Visual identification 
and counting of macrophages and fibroblasts were also used 
to verify the data generated from the image analysis.
Cytokine gene activation
Activation of inflammatory cytokine genes was measured 
using reverse transcription-polymerase chain reactions (PCR). 
Gene expression of the proinflammatory cytokine interleukin-1 
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(IL-1β) was measured in cells obtained from the pouch fluid 
aspirate. Total RNA was extracted from this fluid according to 
the manufacturer’s instructions (Tel-Test, Friendswood, TX). 
A cDNA library was constructed from 5 µg RNA extract 
in 50 µL solution containing 5 µL 10X PCR buffer, 1 µL 
25 mM MgCl2, 20 µL deoxynucleotide triphosphates, 50 units 
RNase inhibitor, 5 µL random hexamers, and 250 units 
reverse transcriptase (Perkin-Elmer Cetus, Norwalk, CT). 
The reaction mixture was incubated for 10 minutes at 25°C, 
25 minutes at 48°C, and 5 minutes at 95°C. The IL-1 primer 
sequence was obtained from Clontech Laboratories Inc 
(Mountain View, CA). A total of 2 µL of cDNA was com-
bined with 25 µL reaction solution containing 0.5 µL primer 
pair, 2.5 µL PCR buffer, 1.5 µL MgCl2, 2 µL nucleotide 
triphosphates (NTPs), and 1.25 U AmpliTaq DNA poly-
merase (Perkin-Elmer Cetus). PCR was initiated by heating 
at 94°C for 1 minute to denature RNA-cDNA hybrids, fol-
lowed by annealing of the primers at 60°C for 1 minute and 
then extension of the primer sequences at 72°C for 1 minute. 
This sequence was repeated 35 times using the DNA thermal 
cycler (Perkin-Elmer Cetus). Following amplification, 10 µL 
of each reaction solution was mixed with 1 µL loading buffer 
for agarose gel electrophoresis. Densities of cytokine bands 
were measured using ultraviolet light and the ISO 2000   Digital 
Imaging System (Alpha Innotech, San Leandro, CA). All 
cytokine levels were normalized using the PCR product from 
the housekeeping gene GAPDH.
Statistics
The analysis of variance (ANOVA) test with post hoc analy-
sis using the least significant difference formula was used 
to compare means for all histological parameters, including 
membrane thickness, density of cellular infiltrate within the 
pouch membrane, and density of cellular infiltrate within the 
cavity of the pouch. When the overall F-test for differences 
among treatment means was significant, pairwise compari-
sons of treatment means were conducted. For the PCR data, 
single-factor ANOVA was again used to test for differences 
among means. When the overall F-test was significant, treat-
ment means were compared using Student’s t-test. All results 
were considered significant for P , 0.05.
Results
Air pouch membrane
The histological characteristics of the air pouch membrane 
were assessed for each of the implanted substances and 
compared with the saline control, because the inflammatory 
response to implanted biomaterials can be characterized by 
increases in both the membrane thickness and the density 
of cellular infiltrate within the membrane wall. In saline-
treated mice, the air pouch membrane was characterized by 
an outer fibrous layer composed primarily of fibroblastic 
cells and an inner portion composed of inflammatory cells, 
predominantly macrophages (Figure 1A). The membranes 
had a mean thickness of 47.7 µm and a cell number of 
83.4 cells/mm2. As shown in Figure 2, pairwise comparisons 
showed a significantly higher membrane thickness for each 
bone graft substitute when compared with the saline control 
(P , 0.05). Additionally, the ProOsteon and the DBX had 
significantly thicker membranes than either of the Accell 
bone graft substitutes (P , 0.05). No other mean differences 
between compounds were significant. The cellular density 
within the air pouch membrane walls did not differ between 
the saline control and any of the compounds tested using 
single-factor ANOVA (data not shown).
Air pouch cellular infiltrate
The density of the cellular infiltrate was examined within the 
air pouch cavity. The cavities of the test compounds each con-
tained regions of immature bone as well as regions of dense 
cellular infiltrates (see Figure 1B–E). As shown in Figure 3, 
using pairwise comparisons, a statistically   significant differ-
AB
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Figure 1 The histological appearance of air pouch membranes from mice implanted 
with saline (A), ProOsteon® (B), DBX® (C), Accell Connexus® (D), and Accell 
DBM-100™ (E). Original magnification = 50× (A, B, D) or 100× (C, E) for larger 
photographs (Bars = 500 microns), 200× for smaller insets (Bars = 100 microns).
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ence in the density of the cellular infiltrate was observed among 
all groups (P , 0.05). ProOsteon showed significantly less 
cellular infiltration than all of the DBM products. Among the 
DBM products, there was an increasing density of the cellular 
infiltrate as the ratio of DBM to carrier increased. The ratio 
of macrophage/monocytes to fibroblasts in the infiltrate was 
determined using image analysis as previously described.20 
Significantly elevated numbers of monocytes were observed 
in pouch tissues associated with Accell Connexus and Accell 
DBM-100 (Figure 4) when compared with the control tissue 
(P , 0.05), whereas the ratios of monocytes:fibroblasts in 
pouch tissues associated with ProOsteon and DBX were not 
significantly different from control pouch tissues.
Cytokine gene activation in the air pouch
Reverse transcription-PCR was performed using the mRNA 
extracted from cells within the pouch fluid. Murine IL-1 
primers were used to determine IL-1 expression as a marker 
to quantify the inflammatory reaction within the cavity of 
the pouch. Results are shown in Figure 5. Compared with 
the saline control, all compounds showed significantly 
higher levels of IL-1 expression (P , 0.05). The highest 
level of IL-1 expression was observed in the Accell DBM-
100-containing air pouches; the increased expression was 
statistically significant when compared with both ProOsteon 
and Accell Connexus (P , 0.05).
Discussion
Recent studies have helped to clarify the optimum makeup 
of DBM products, including the source of allograft, prepara-
tion methods, particle size, and different carrier   substances.21 
Several studies have suggested that differing methods 
of graft preparation can cause differences in efficacy.14,22 
Unfortunately, few studies have examined how differences 
in bone graft substitute production may cause variations in 
biocompatibility with adverse effects.
All DBM products are prepared from bone allografts that 
are first treated with a variety of washes, antibiotic treatments, 
irradiation, and other treatments to remove potentially infec-
tious agents. In addition to removing bacterial contaminants, 
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Figure 2 Membrane thickness of control and bone graft substitute-stimulated air 
pouches.
Notes: aP , 0.05 versus saline control. n = 6 mice/group.
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Figure 3 Membrane cellularity within the cavity of the pouch of control and bone 
graft substitute-stimulated mice.
Notes: aP , 0.05 versus saline control. n = 6 mice/group.
Abbreviation: SE, standard error
Ratio of 
Monocytes:Fibroblasts:
Monocytes
Fibroblasts
100
80
60
40
20
0
Saline Accell
Connexus®
P
e
r
c
e
n
t
a
g
e
 
o
f
 
t
o
t
a
l
 
c
e
l
l
s
 
(
m
e
a
n
 
±
 
S
E
,
 
%
)
Accell
DBM-100™
DBX® ProOsteon®
1:4 1:1.2a 1:2.3a 1:4 1:3.3
Figure 4 Ratio of macrophages/monocytes to fibroblasts within the air pouch of 
control and bone graft substitutes.
Notes: aP , 0.05 versus saline control. n = 6 mice/group.
Abbreviation: SE, standard error
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Figure 5 Interleukin-1 gene copies produced using reverse transcription-polymerase 
chain reaction with mRnA extracted from the air pouches of control and bone graft 
substitute-stimulated mice.
Notes: aP , 0.05 versus saline control. n = 6 mice/group.
Abbreviations: Se, standard error; mRnA, messenger ribonucleic acid.
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processing has been shown to inactivate multiple infectious 
viruses, including human immunodeficiency virus, hepatitis 
B and C viruses, and cytomegalovirus.23,24 It is not yet clear 
whether differences in efficacy result from differences in the 
carriers or are as a result of other differences in preparation. 
The tissue is then demineralized using an acid solution, usu-
ally hydrochloric acid. Finally, the DBM is then mixed with a 
carrier to alter the texture, viscosity, and other characteristics 
of the final packaged product.
There are other factors that can affect the efficacy and 
safety of DBM products. Animal and human studies have 
shown that the age of the donor can significantly impact 
the osteoinductive potential for DBM.25,26 There are also 
significant differences in the type of carrier used and in the 
concentration of DBM within that carrier. Different carriers 
include glycerol, porcine collagen, hyaluronic acid, lecithin, 
calcium sulfate, or no carrier at all. Most DBM products con-
tain approximately 20%–40% DBM by weight. In addition to 
the carrier substance in the DBM product, some investigators 
have also looked at various additional delivery systems added 
at the time of implantation to further alter the physical proper-
ties of the DBM.27,28 The fact that there are so many different 
materials and techniques used to manufacture similar products 
all intended for the same purpose means that the ideal makeup 
of a bone graft substitute is as yet undefined.
This study was designed to examine the inflammatory 
characteristics of several commercially available bone 
graft substitutes. Three demineralized bone graft products 
and one synthetic hydroxyapatite compound were studied 
using the murine air pouch.19 Overall, all products showed 
a significant inflammatory response within the pouch when 
compared with the saline control (summarized in Table 1). 
The hydroxyapatite material showed less inflammation than 
the DBM products. Within the DBM products tested, there 
was a trend toward increasing inflammation with increasing 
DBM concentration. The precise mechanism for this relation-
ship remains to be determined and should be addressed in the 
clinical setting, given that a wide variety of DBM products 
with different DBM to carrier ratios are available.
With regard to the efficacy of different DBM products, 
Peterson et al29 recently published a study comparing mul-
tiple commercially available DBM products using an animal 
spinal fusion model with three different DBM preparations. 
They showed significant differences in the fusion rate and 
osteoinductive activity seen on histological sections.29 The 
animal model utilized immunoincompetent, athymic mice, 
which unfortunately precluded the evaluation of any effects 
of immune-provoked inflammation on osteoinductivity.
There were two weaknesses to our model of testing for 
the inflammatory reaction induced by bone graft substitutes. 
First, an animal model was employed. Any analogies to 
human biology must be made with caution. Species-specific 
reactivity to biomaterials should be considered. Specifically, 
the DBM products were derived from human tissue and 
theoretically could elicit a xenograft reaction not pertinent 
to human implantation. Second, this study was designed to 
elucidate the inflammatory reaction caused by these materi-
als, and the cytokine evaluation was restricted to the mea-
surement of IL-1β, the major mediator elicited in the murine 
inflammatory air pouch. No assertions were made relative 
to their efficacy. Therefore, one should use caution when 
extrapolating from the data presented here to determine the 
ideal bone graft substitute. Further studies are needed to 
discover the ideal formulation for a bone graft substitute. 
A follow-up to this study could include the examination of 
additional bone graft substitutes. Moreover, bone tissue can 
be implanted within the air pouch with bone graft substitute 
materials to quantify bone induction and production. Ulti-
mately, randomized, prospective clinical trials comparing 
these products should be undertaken. However, studies such 
as ours help shed some light on the complex biology of bone 
graft substitutes.
Conclusion
By both histologic and biochemical markers, our results indi-
cate that all the products investigated provoked a significant 
inflammatory reaction when compared with the saline con-
trol. DBM products showed more inflammation than coralline 
Table 1 Summary of data from histological analyses and reverse transcription-polymerase chain reaction analysis
Bone graft 
substitute
Membrane thickness 
(mean ± SE, μm)
Pouch density  
(mean ± SE, cells/mm2)
Macrophages/monocytes: 
fibroblasts
Interleukin-1 expression 
(mean ± SE, copies)
Saline   47.7 ± 2.4   1.0 ± 0.2 1:4   50,609 ± 24,083
ProOsteon® 166.7 ± 7.2   30.7 ± 1.2 1:3.3 113,930 ± 23,715
DBX® 202.3 ± 8.7   63.1 ± 1.0 1:4 167,203 ± 50,079
Accell Connexus® 124.8 ± 6.5   96.0 ± 1.6 1:1.3 146,115 ± 44,487
Acell DBM-100™ 134.4 ± 6.3 107.7 ± 2.2 1:2.3 377,137 ± 83,669
Abbreviation: SE, standard error.
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hydroxyapatite. Within the DBM groups, there was a trend 
toward increasing inflammation with increasing DBM con-
centration. Therefore, our preliminary findings suggest that 
DBM products with varied DBM proportions may influence 
the level of biocompatibility during clinical use.
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